Literature DB >> 3742841

Bile acid-induced diarrhoea.

H Fromm, M Malavolti.   

Abstract

Three types of bile acid-induced diarrhoea can be distinguished. The best documented and most common entity is represented by type I bile acid malabsorption, which occurs as the result of a pathologically, anatomically defined ileopathy. Type II bile acid malabsorption is found in the setting of a morphologically completely normal ileum. This primary disorder of bile acid transport, which has been described in only a few paediatric and adult patients, appears to be rare. The third variety of bile acid malabsorption is characterized by the history of a previous cholecystectomy and/or by the presence of other gastroenterological conditions. Severe bile acid malabsorption is relatively uncommon in the type III syndrome. Even in the presence of severe bile acid malabsorption, patients with this condition are rarely found to have secretory concentrations of faecal bile acids, and/or rarely respond satisfactorily to cholestyramine. Present data suggest that bile acids play no significant role in the pathogenesis of idiopathic diarrhoea. A careful history, the measurement of stool weight and pH, a therapeutic trial of cholestyramine and the performance of a bile acid test, such as a bile acid breath test, can be used to establish the diagnosis of bile acid diarrhoea. Cholestyramine is the treatment of choice and is virtually always effective in this syndrome.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3742841

Source DB:  PubMed          Journal:  Clin Gastroenterol        ISSN: 0300-5089


  32 in total

1.  Disorder of bile acid metabolism in children with short bowel syndrome.

Authors:  N Ohkohchi; T Andoh; U Izumi; Y Igarashi; R Ohi
Journal:  J Gastroenterol       Date:  1997-08       Impact factor: 7.527

2.  Managing bile acid diarrhoea.

Authors:  Julian R F Walters; Sanjeev S Pattni
Journal:  Therap Adv Gastroenterol       Date:  2010-11       Impact factor: 4.409

3.  Bile Acid Deficiency in a Subgroup of Patients With Irritable Bowel Syndrome With Constipation Based on Biomarkers in Serum and Fecal Samples.

Authors:  Priya Vijayvargiya; Irene Busciglio; Duane Burton; Leslie Donato; Alan Lueke; Michael Camilleri
Journal:  Clin Gastroenterol Hepatol       Date:  2017-06-27       Impact factor: 11.382

4.  Loss of absorptive capacity for sodium chloride as a cause of diarrhea following partial ileal and right colon resection.

Authors:  K A Arrambide; C A Santa Ana; L R Schiller; K H Little; W C Santangelo; J S Fordtran
Journal:  Dig Dis Sci       Date:  1989-02       Impact factor: 3.199

5.  Treatment of severe steatorrhea with ox bile in an ileectomy patient with residual colon.

Authors:  K H Little; L R Schiller; L E Bilhartz; J S Fordtran
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

6.  Ten Reasons to Think about Bile Acids in Managing Inflammatory Bowel Disease.

Authors:  Michael Camilleri
Journal:  J Crohns Colitis       Date:  2020-08-31       Impact factor: 9.071

7.  Bile acid malabsorption in microscopic colitis and in previously unexplained functional chronic diarrhea.

Authors:  F Fernandez-Bañares; M Esteve; A Salas; T M Forné; J C Espinos; J Martín-Comin; J M Viver
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

8.  Diet1, bile acid diarrhea, and FGF15/19: mouse model and human genetic variants.

Authors:  Jessica M Lee; Jessica R Ong; Laurent Vergnes; Thomas Q de Aguiar Vallim; Jonathan Nolan; Rita M Cantor; Julian R F Walters; Karen Reue
Journal:  J Lipid Res       Date:  2018-01-02       Impact factor: 5.922

9.  Performance characteristics of serum C4 and FGF19 measurements to exclude the diagnosis of bile acid diarrhoea in IBS-diarrhoea and functional diarrhoea.

Authors:  P Vijayvargiya; M Camilleri; P Carlson; A Lueke; J O'Neill; D Burton; I Busciglio; L Donato
Journal:  Aliment Pharmacol Ther       Date:  2017-07-10       Impact factor: 8.171

10.  Use of the SeHCAT test in the investigation of diarrhoea.

Authors:  G A Ford; J D Preece; I H Davies; S P Wilkinson
Journal:  Postgrad Med J       Date:  1992-04       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.